MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Genome-wide association studies of motor and cognitive progression in Parkinson’s disease

M. Tan, L. Hubbard, M. Lawton, S. Kanavou, N. Wood, J. Hardy, Y. Ben-Shlomo, N. Williams, D. Grosset, H. Morris (London, United Kingdom)

Meeting: 2018 International Congress

Abstract Number: 1354

Keywords: Cognitive dysfunction, Parkinsonism

Session Information

Date: Monday, October 8, 2018

Session Title: Parkinson's Disease: Genetics

Session Time: 1:15pm-2:45pm

Location: Hall 3FG

Objective: Motor and cognitive progression in Parkinson’s is heterogeneous. Our aim is to identify single nucleotide polymorphisms (SNPs) associated with disease progression.

Background: Rare genetic variants, such as GBA, have been shown to predict mortality and motor progression in Parkinson’s disease. There is early evidence from small studies that common genetic variants and the cumulative Genetic Risk Score are also associated with motor and cognitive decline [1,2].

Methods: 1987 patients with recent-onset Parkinson’s disease were recruited to the Tracking Parkinson’s study in the UK. DNA samples were genotyped using the Illumina HumanCore Exome array with custom content and imputed using the Haplotype Reference Consortium panel v1.1. Motor progression was defined as annual change in the MDS-UPDRS Part III scores from baseline to 18 months (on/off medication) and 24 months (off medication). Cognitive progression was defined as annual change in Montreal Cognitive Assessment (MoCA) scores from baseline to 18 months. We conducted unbiased Genome Wide Association Studies (GWASs) with linear regression models to search for associated variants across the genome. Age at onset, sex and population structure (10 principal components) were included as covariates.

Results: 33 patients were excluded because they received a different diagnosis other than Parkinson’s. Early results from the motor progression GWAS showed that one loci in Chromosome 3 is significantly associated with change in MDS-UPDRS Part III score (on or off medication) at 18 months, p<5x10^-8. When we conducted a GWAS using MDS-UPDRS Part III data in the ‘off’ medication state, several loci in Chromosomes 3, 10, 7 and 11 reached nominal significance (p<5x10^-5) but none reached genome-wide significance. For cognitive progression, no SNPs reached genome-wide significance. However several loci in Chromosome 7, 4 and 11 reached nominal significance. We will take these variants forward for replication in independent cohorts and investigate the biological plausibility using gene expression analysis, pathway analysis and comparison with exome data.

Conclusions: Our pilot analyses show early evidence that common genetic variants may be associated with motor and cognitive progression but longer follow-up is required. Genetic variants that are associated with progression could potentially be investigated as targets for new therapies to stop or slow disease progression.

References: 1. Paul KC, Schulz J, Bronstein JM, Lill CM, Ritz BR. Association of Polygenic Risk Score With Cognitive Decline and Motor Progression in Parkinson Disease. JAMA Neurol. 2018. doi:10.1001/jamaneurol.2017.4206. 2. Latourelle JC, Beste MT, Hadzi TC, et al. Large-scale identification of clinical and genetic predictors of motor progression in patients with newly diagnosed Parkinson’s disease: A longitudinal cohort study and validation. Lancet Neurol. 2017;16(11):908-916. doi:10.1016/S1474-4422(17)30328-9.

To cite this abstract in AMA style:

M. Tan, L. Hubbard, M. Lawton, S. Kanavou, N. Wood, J. Hardy, Y. Ben-Shlomo, N. Williams, D. Grosset, H. Morris. Genome-wide association studies of motor and cognitive progression in Parkinson’s disease [abstract]. Mov Disord. 2018; 33 (suppl 2). https://www.mdsabstracts.org/abstract/genome-wide-association-studies-of-motor-and-cognitive-progression-in-parkinsons-disease/. Accessed May 13, 2025.
  • Tweet
  • Email
  • Print

« Back to 2018 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/genome-wide-association-studies-of-motor-and-cognitive-progression-in-parkinsons-disease/

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • The hardest symptoms that bother patients with Parkinson's disease
  • Life expectancy with and without Parkinson’s disease in the general population
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • The hardest symptoms that bother patients with Parkinson's disease
  • Life expectancy with and without Parkinson’s disease in the general population
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • The hardest symptoms that bother patients with Parkinson's disease
  • Three cases of early tremor in the course of Guillain-Barré Syndrome
  • The impact of gastric acid suppressants and antacids on levodopa plasma concentration in patients with Parkinson’s disease
  • To be or not to bupropion: a drug-induced parkinsonism?
  • The Role of MRI and DaTscan in Vascular Parkinsonism: A Case Report
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley